Loading...
Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Acquired thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease characterized by thrombotic microangiopathy leading to end-organ damage. The standard of care (SOC) treatment is therapeutic plasma exchange (TPE) alongside immunomodulation with steroids, with increasing use of rituxim...
Na minha lista:
| Udgivet i: | Blood |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7918179/ https://ncbi.nlm.nih.gov/pubmed/33280030 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020006052 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|